Drug General Information (ID: DDIN13BT4S)
Drug Name			Daptomycin		Drug Info		Bromfenac		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antibiotics				Antiinflammatory Agents
Structure

Mechanism of Daptomycin-Bromfenac Interaction (Severity Level: Moderate)
Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Daptomycin				Bromfenac
Mechanism		Nephrotoxicity				Nephrotoxicity
Key Mechanism Factor 1
		Factor Name		Nephrotoxicity
		Factor Description		The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
Mechanism Description		Increased risk of nephrotoxicity by the combination of Daptomycin and Bromfenac

Recommended Action
Management		Serum drug concentrations and renal function, including serum creatinine, should be carefully monitored during concurrent administration. In addition, all patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more).

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".